Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 1

Status

Recruiting 3Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 4NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 60Gastrointestinal 31Endocrine 15CNS 14Thoracic 9Sarcoma 9Head & Neck 9NET 8Tumor-Agnostic 7Breast 6Plasma cell 4Gynecologic 3Dermatologic 3Other solid neoplasm 2Other hematologic neoplasm 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms 5Neoplasm Metastasis 3

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × cabozantinib × Tumor-Agnostic × Clear all
NCT03611595 2026-05-27

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

University of California, San Diego

Phase 1 Completed
15 enrolled
Tumor-Agnostic

Neoplasms

NCT04116541 2026-04-24

MegaMOST

Centre Leon Berard

Phase 2 Recruiting
455 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05502315 2026-01-23

CANOPY

Hoosier Cancer Research Network

Phase 2 Recruiting
47 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05289856 2024-03-07

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Johannes Gutenberg University Mainz

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT01428219 2017-12-12

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

University of Michigan Rogel Cancer Center

Phase 2 Terminated
25 enrolled 12 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡